Mehta Vimal
CEO and President
Mehta Vimal has filed 6 SEC Form 4 filings (10 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Jun 17, 2026.
On the most recent filing, Mehta Vimal is listed as CEO and President at BioXcel Therapeutics, Inc. Inside the rolling window, Mehta Vimal reported no open-market purchases and 1 open-market sale totaling $21K in BTAI.
Companies traded
Other insiders at BTAI
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$21K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Mehta Vimal made?
Mehta Vimal has filed 6 SEC Form 4 filings (10 transaction rows) across 1 company since 2025.
Which companies does Mehta Vimal trade?
Mehta Vimal has filed SEC Form 4 disclosures for 1 company, including BTAI.
When was Mehta Vimal's most recent SEC Form 4 filing?
Mehta Vimal's most recent SEC Form 4 filing on Tracefour is dated Jun 17, 2026.
What is Mehta Vimal's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Mehta Vimal is listed as CEO and President.
What is Mehta Vimal's total buy and sell value in the current window?
Inside the rolling retention window, Mehta Vimal bought $0 and sold $21K based on SEC Form 4 filings.
What was Mehta Vimal's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 19,419 BTAI shares on 2026-05-20, worth $21K, per SEC Form 4 filings.